{"id":"human-vwf-fviii-concentrate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Pain at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This drug works by providing the necessary clotting factors to help the blood to clot properly. It is used to prevent or control bleeding episodes in patients with hemophilia A, a genetic disorder that impairs the body's ability to make blood clots.","oneSentence":"Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:20.333Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A"},{"name":"Surgery in patients with hemophilia A"}]},"trialDetails":[{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT06205095","phase":"PHASE3","title":"A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD","status":"RECRUITING","sponsor":"Unity Health Toronto","startDate":"2024-10-21","conditions":"Von Willebrand Diseases","enrollment":20},{"nctId":"NCT02472665","phase":"PHASE4","title":"Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease","status":"RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2013-12","conditions":"Von Willebrand Disease","enrollment":8},{"nctId":"NCT00555555","phase":"PHASE4","title":"Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grifols Biologicals, LLC","startDate":"2007-09","conditions":"Von Willebrand Disease","enrollment":15},{"nctId":"NCT01051544","phase":"NA","title":"Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2009-09-25","conditions":"Severe Hemophilia A","enrollment":""},{"nctId":"NCT02552576","phase":"PHASE4","title":"Study of Voncento® in Subjects With Von Willebrand Disease","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2015-10-05","conditions":"Von Willebrand Disease","enrollment":26},{"nctId":"NCT00941616","phase":"PHASE2, PHASE3","title":"Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2009-06","conditions":"Von Willebrand Disease","enrollment":22},{"nctId":"NCT02479087","phase":"PHASE4","title":"Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2015-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT01365546","phase":"PHASE3","title":"Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery","status":"COMPLETED","sponsor":"Octapharma","startDate":"2011-06","conditions":"Prevent Bleeding in Major Surgery","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"human VWF/FVIII concentrate","genericName":"human VWF/FVIII concentrate","companyName":"Octapharma","companyId":"octapharma","modality":"Biologic","firstApprovalDate":"","aiSummary":"Human VWF/FVIII concentrate replaces clotting factors in the blood to prevent or control bleeding episodes in patients with hemophilia A. Used for Hemophilia A, Surgery in patients with hemophilia A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}